942404-97-9

Upstream product

• 89-57-6 5-Aminosalicylic Acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 42753-75-3 methyl 5-amino-2-hydroxybenzoate 

Downstream Products

• 1596360-82-5 9H-fluoren-9-ylmethyl N-[(5S)-5-[[6-[[3-[3-carbamoyl-4-(4-pyridylmethoxy)phenyl]-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carbonyl]amino]-5-cyano-pentyl]carbamate 
• 1596360-39-2 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[3-[3-carbamoyl-4-(4-pyridylmethoxy)phenyl]-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596361-01-1 tert-butyl N-[3-carbamoyl-4-(4-pyridylmethoxy)phenyl]carbamate 
• 1596361-02-2 ethyl 2-[[3-carbamoyl-4-(4-pyridylmethoxy)phenyl]amino]acetate 
• 1596360-11-0 5-(2,4-dioxoimidazolidin-1-yl)-2-(4-pyridylmethoxy)benzamide 
• 1596360-59-6 methyl 6-[[3-[3-carbamoyl-4-(4-pyridylmethoxy)phenyl]-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxylate 
• 1596361-00-0 methyl 5-(tert-butoxycarbonylamino)-2-(4-pyridylmethoxy)benzoate 
• 1282038-84-9 C₂₀H₂₃NO₅ 

Relevant academic research and scientific papers

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

TREATMENT OF OBESITY AND PULMONARY ARTERIAL HYPERTENSION

Disclosed are methods and compositions for treating pulmonary arterial hypertension and/or obesity using inhibitors of prostaglandin transporter (PGT) activity.

HETEROCYCLIC COMPOUNDS

The present invention relates to novel pyrimidine class of compounds, their pharmaceutically acceptable salts, and pharmaceutically acceptable compositions containing them and their use in medicine.